Skip to main content
GRAL logo

GRAL · GRAIL, Inc.

Track GRAL — free
$108.48 +6.38 (+6.25%)
Market Cap
$4.59B
Shares
44.96M
Volume · Nov 19 198.29K Avg daily vol (3M) 1.06M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$102.10 Open$106.28 Day$101.34–107.32 52W close$43.03–158.92 Avg vol 30d875K Short int8.0M · 17.8% of shares · 8.7d Short vol55% Last earningsNov 4, 2026 DataJun 2024–Nov 2026 Filing10-Q · Nov 5

Up next

Feb 18, 2027 Est · unconfirmed · in 13 wks

Latest documents

2026
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
FDA panel backs Galleri ahead of approval decision

GRAIL’s Galleri received favorable FDA advisory committee support: unanimous on safety, six to four on effectiveness and seven to two with one abstention on benefits outweighing risks. GRAIL expects an FDA decision by early first quarter of 2027.

Revenue $37.54M ▲ 3.7% Net loss $103.57M Diluted EPS -$2.21
Read from the MD&A section
4 source passages
In September 2026, the FDA’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee voted in favor of Galleri’s safety, effectiveness and overall benefit-risk profile for screening for the early detection of multiple types of cancer in adults aged 50 years and older. The advisory committee voted unanimously in support of Galleri’s safety, six to four in support of Galleri’s effectiveness, and seven to two with one abstention that the benefits of Galleri outweigh its risks. We expect a final decision by the FDA on our PMA by early first quarter of 2027. references to "GRAIL," “we,” “us,” and the "Company" refer to GRAIL, Inc. Open the document at this passage
Nov 4
Earnings call
FDA decision expected by early Q1 of 2027

GRAIL expects an FDA decision on Gallery by early Q1 of 2027 after a favorable advisory committee vote. Third-quarter revenue was $37.5 million, test volumes increased 24%, and full-year Gallery sales growth guidance was updated to 17% to 21%.

5 source passages
GRAIL achieved multiple significant milestones this quarter, including a favorable vote for approval from the FDA's advisory committee and the publication of NHS Gallery and Pathfinder 2 results in the New England Journal of Medicine and Nature Medicine. We're engaged in interactive communications with the FDA since the Advisory Committee, and we expect to receive a final decision by early Q1 of 2027. In Q3, we reported revenue of $37.5 million, up $1.3 million, or 4%, as compared to the third quarter of 2025. Test volumes increased 24% in Q3 as compared to the prior year As we look towards the end of the year, we are updating our guidance for the full-year gallery sales revenue growth to be 17% to 21%. Open the document at this passage
Nov 4
Current report 8-K
Galleri wins favorable FDA advisory committee vote

GRAIL reported an FDA advisory committee vote favoring Galleri approval and anticipates a decision by early Q1 2027. Third-quarter Galleri revenue grew 14% to $37.3 million, while net loss widened to $103.6 million.

Financial results
4 source passages
“GRAIL achieved significant milestones this quarter including a favorable vote for approval of Galleri at the FDA Advisory Committee,” said Josh Ofman, MD, MSHS, Chief Executive Officer of GRAIL. The company anticipates an FDA decision by early Q1 2027. Galleri test revenue for the third quarter grew 14% year-over-year to $37.3 million, and total revenue grew 4% year-over-year to $37.5 million. Net loss for the third quarter was $103.6 million. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$166.60M
Trailing 12 months
Net income (TTM)
−$406.18M
Trailing 12 months
Revenue growth YoY
+3.7%
Year over year
Operating margin
-347.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-6.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$28.98M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+29.5%
Year over year · more shares
Price change (1Y)
+25.3%
Trailing year
Short interest
17.8%
Latest settlement · 8.7 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 4, 2026
Q3 FY26

TL;DR. Galleri received favorable FDA Advisory Committee support, delivered strong clinical detection results, and continued growing test volume and revenue, while GRAIL ended Q3 with $788.7 million in cash and runway into 2029. Financial pressure remains elevated, with Q3 losses, weaker adjusted gross margin, lower ASPs, a returning Illumina royalty, competitive headwinds, and no combined reduction in Stage III and IV cancers.

Bullish
  • + The FDA Advisory Committee voted in favor of Galleri approval, with a decision expected by early Q1 2027.
  • + The NHS-Galleri and PATHFINDER 2 studies demonstrated substantially increased cancer detection with robust performance and a favorable safety profile.
  • + The NHS-Galleri trial reported more than a 20% reduction in Stage IV diagnoses across 12 prespecified aggressive cancers and a 25% reduction in cancers diagnosed after emergency presentation.
  • + Q3 Galleri test volume increased approximately 24% year-over-year to more than 56,000 tests.
  • + Galleri revenue grew 14% year-over-year to $37.3 million in Q3.
  • + GRAIL ended Q3 with $788.7 million in cash and expects that balance to provide runway into 2029.
Bearish
  • − Q3 produced a $103.6 million net loss, an $18.1 million gross loss and a $92.6 million adjusted EBITDA loss.
  • − Adjusted gross margin fell to 42% in Q3 from 55% a year earlier.
  • − Promotional pricing reduced Q3 ASP to approximately $660 per test as GRAIL prioritized growth and penetration over margin optimization.
  • − The suspended Illumina royalty is scheduled to resume in late December 2026 and will fully pressure first-quarter 2027 gross margin; it would have been $2.6 million in Q3.
  • − Negative marketplace headlines and an active competitive environment tempered Q3 growth.
  • − The NHS Gallery trial did not observe a combined reduction in Stage III and IV cancers.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +29%
above
Price vs 50-day avg −17%
below
RSI (14) 36
neutral
MACD trend Negative
52-week position 51%
mid-range
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Strong
1-month return −23%
trailing
6-month return +38%
trailing
YTD return +19%
this year
Relative strength +42%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $122 › 200d $79 — 50d above 200d
Institutional flow Accumulating
+19% holders QoQ · +113 funds added
Insider flow Distributing
Net -$4.6M over 90 days · 100% sells
Short interest Falling
17.79% of shares out · ▼ -2.2% MoM · 8.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
458 holders — near 3-yr high, broad support
Squeeze score 73
high risk · 0–100
Fundamentals
Strong
Revenue growth +17%
Y/Y
EPS growth +83%
Y/Y
Free cash flow $-299.9M
Balance sheet $249.7M
net cash
Quant / Vol
risk profile
Very High
Volatility 103%
annualized · 1-yr
Max drawdown −63%
past year
ATR 10.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Jan 12, 2026
Cash burn · 2026 up to $300M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
2 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+29% Bullish
Price vs 50-day avg
−17% Bearish
RSI (14)
36 Neutral
MACD trend
Negative Bearish
52-week position
51% Neutral
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $122 › 200d $79 — 50d above 200d
Institutional flow Accumulating
+19% holders QoQ · +113 funds added
Insider flow Distributing
Net -$4.6M over 90 days · 100% sells
Short interest Falling
17.79% of shares out · ▼ -2.2% MoM · 8.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
458 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $43 Now $102 · 51% Range high $159
vs 200-day avg +29% vs 50-day avg -17%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA non-GAAP -170.19M Six Months Ended June 30, 2026 —
Adjusted Gross Profit non-GAAP 41.25M Six Months Ended June 30, 2026 —
Galleri test volume 61,000 second quarter of 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Diagnostics & Research — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
GRAL
GRAIL, Inc.
this stock
$4.59B +19.3% +17.2% — 17.8%
TMO
Thermo Fisher Scientific Inc.
$256.67B +19.6% +14.5% 36.5 1.3%
DHR
Danaher Corp
$160.81B -0.1% +8.5% 37.4 1.2%
IDXX
Idexx Laboratories Inc
$55.03B +3.2% +10.4% 47.1 3.0%
A
Agilent Technologies, Inc.
$49.99B +30.3% +6.4% 34.9 1.7%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
458
% held
84.8%
Net QoQ
+48.4K sh
Top holder
FARALLON CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
240
View
Short & Settlement
Short Interest Falling
Shares short
8.0M
Days to cover
8.7d
Change
-176.0K sh
View
Short Volume
Short vol %
55%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
745
Value
$87.8K
As of
Oct 19, 2026
View
Off-Exchange
Off-exchange %
41.4%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$4.6M
Buyers / Sellers
0 / 2
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$147.2M
Net income (FY)
$-408.4M
EPS diluted
$-11.11
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 5, 2026
This year
17

GRAIL’s Galleri received favorable FDA advisory committee support: unanimous on safety, six to four on effectiveness and seven to two with one abstention on benefits outweighing risks. GRAIL expects an FDA decision by early first quarter of 2027.

View
Proposed Sales
Value
$695.3K
Shares
6.0K
Filed
Nov 16, 2026
View
Exempt Offerings
Offering
$325.0M
Filed
Nov 7, 2025
View
Earnings & Events
Webcasts
Last webcast
Nov 10, 2026
View
Investor Relations
Latest news
GRAIL Reports Third Quarter 2026…
Published
Nov 4, 2026
View

Performance

5D 20D 120D MTD YTD
GRAL -18.7% -23.0% +38.1% -28.8% +19.3%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY -14.8% -17.5% +41.6% -25.4% +12.2%
Key facts CIK 1699031 CUSIP 384747101 13F (30d) 456 filings 412 filers Visit website Investor relations